However, as observed in primary tumours, MCT2 protein expression was selectively increased in malignant tissue compared to adjacent non-neoplastic tissue and MCT2 expression persists in drug-resistant tumours (Figure 2J), suggesting that elevated MCT2 expression is maintained throughout PCa development from neoplasia to late stage, drug-resistant tumours (Figure 2J), underscoring MCT2 as a marker for malignant PCa and as a potential target for therapy. Here, SLC16A7 is linked to posterior cortical atrophy.